Skip to main content

Thermo Fisher Scientific cash and equivalents

  • TMO · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$700.22+0.11%Close 13 Nov 2026

Thermo Fisher Scientific's cash and equivalents was $9.85 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 146% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 26 Sep 2026) it was $5.46 billion, up 176% from a year earlier.

From Thermo Fisher Scientific's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Fiscal 2025
$9.85B
+146%
Q3 FY2026
$5.46B
+176% on a year
Growth over 9 years
+32.4%
a year, FY 2016–FY 2025

Cash and equivalents by fiscal year

$786MFY 2016$1.33BFY 2017+69.8%$2.10BFY 2018+57.5%$2.40BFY 2019+14.1%$10.3BFY 2020+330%$4.48BFY 2021−56.6%$8.52BFY 2022+90.4%$8.08BFY 2023−5.2%$4.01BFY 2024−50.4%$9.85BFY 2025+146%

Change on the year before, under each year. From FY 2016 to FY 2025, Thermo Fisher Scientific's cash and equivalents went from $786 million to $9.85 billion, a compound annual change of +32.4%; the highest was $10.3 billion in FY 2020.

Thermo Fisher Scientific cash and equivalents, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$786M$1.33B$2.10B$2.40B$10.3B$4.48B$8.52B$8.08B$4.01B$9.85B
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Cash and equivalents by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Thermo Fisher Scientific cash and equivalents, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$4.01B$4.13B$4.58B$1.98B$9.85B$3.25B$4.06B$5.46B
Period end31 Dec 202429 Mar 202528 Jun 202527 Sep 202531 Dec 202528 Mar 202627 Jun 202626 Sep 2026

How cash and equivalents is measured

Cash and equivalents is the cash the company holds at the end of the period and the investments it can turn into cash within three months. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Thermo Fisher Scientific's other figures

Cash and equivalents of comparable companies

Everything on TMO, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.